If the plug-in named ChemScape Chime
is properly installed on your computer, you should see a 3D 6-TG molecule.
The molecule can be moved by clicking it with the left button of
your mouse and its characteristics, including automatic rotation, can
be modified by clicking it with the right button.
This molecule has been drawn by using the ISIS/Draw
software, saved as a *.mol file, converted to a SMILES
string by Chem
Draw, and its 3D model has been generated by CORINA
as a *.pdb file by M. Presta.
Would do like to know more about 6-TG?:
CambridgeSoft
provides a database of 2,500 micromolecules which can be searched at no
cost with their utility ChemFinder
from the web.
To download the plug-in: 
.
The antimetabolite 6-thioguanine (6-TG) is utilized in the management of acute myelogenous leukemia (AML). Angiogenesis is a possible therapeutic target in hematologic tumors. Thus, we addressed the possibility that 6-TG may also act as an anti-angiogenic molecule.
6-TG inhibited endothelial cell proliferation triggered by Fibroblast Growth Factor-2 (FGF2) and Vascular Endothelial Growth Factor (VEGF) and delayed the repair of a mechanically wounded endothelial cell monolayer. Also, 6-TG inhibited sprouting within fibrin gel, morphogenesis on Matrigel, and collagen gel invasion by endothelial cells. 2-Aminopurine was ineffective.
In vivo, 6-TG inhibited basal, VEGF-induced, and FGF2-induced vascularization in the chick embryo chorioallantoic membrane and prevented neovascularization triggered by leukemia LIK cells or their conditioned medium.
Finally, bone marrow vascularization in AML patients was decreased to control values in the early remission phase and persisted unvaried after 8-12 months of maintenance therapy with 6-TG.
Thus, 6-TG inhibits different steps of the angiogenesis
process in vitro and exerts a potent anti-angiogenic activity in vivo.
Its antiangiogenic activity, together with its antimetabolite activity
towards tumor cells, may contribute to its action during maintenance therapy
in AML. These results suggest a new rationale for the use of purine analogs
in the management of AML.
Leukemia, (2002) 16:1490-1499.
